Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Apr;145(4):873-879.
doi: 10.1007/s00432-019-02850-1. Epub 2019 Feb 13.

Prevalence and clinical significance of RBM3 immunostaining in non-small cell lung cancers

Nathaniel Melling  1 , Kai Bachmann  1 , Bianca Hofmann  1 , Alexander Tarek El Gammal  1 , Matthias Reeh  1 , Oliver Mann  1 , Christoph Moebius  2 , Marco Blessmann  2 , Jakob Robert Izbicki  1 , Katharina Grupp  3   4
Affiliations

Prevalence and clinical significance of RBM3 immunostaining in non-small cell lung cancers

Nathaniel Melling et al. J Cancer Res Clin Oncol. 2019 Apr.

Abstract

Introduction: Aberrant expression of RNA-binding motif protein 3 (RBM3) has been suggested as a prognostic biomarker in several malignancies.

Materials and methods: This study was performed to analyse the prevalence and clinical significance of RBM3 immunostaining in non-small cell lung cancers (NSCLCs). Therefore, we took advantage of our tissue microarray (TMA) containing more than 600 NSCLC specimens.

Results: While nuclear RBM3 staining was always high in normal lung tissue, high RBM3 staining was only seen in 77.1% of 467 interpretable non-metastatic NSCLCs. Reduced RBM3 staining was significantly associated with advanced pathological tumor stage (pT) in NSCLCs (p = 0.0031). Subset analysis revealed that the association between reduced RBM3 staining and advanced pT stage was largely driven by the histological subgroup of lung adenocarcinoma (LUACs) (p = 0.0036). In addition, reduced RBM3 expression predicted shortened survival in LUAC patients (p = 0.0225).

Conclusions: In summary, our study shows that loss of RBM3 expression predicts worse clinical outcome in LUAC patients.

Keywords: Immunohistochemistry; Large cell lung carcinoma; Lung adenocarcinoma; Non-small-cell lung carcinoma; RBM3; Squamous cell lung carcinoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Immunohistochemical staining with RBM3 protein in LUACs, LCLCs, and SQCCs of the lung. Low and high RBM3 expression in LUACs (a, b), LCLCs (c, d), and SQCCs (e, f) of the lung
Fig. 2
Fig. 2
Kaplan–Meier curves for overall survival of NSCLC patients. Associations of RBM3 immunostaining with overall survival of all NSCLC patients (a) and the subsets of LUAC (b), LCLC (c), and SQCC (d) patients
See this image and copyright information in PMC

References

    1. Al-Fageeh MB et al (2009) Cold-inducible RNA binding protein (CIRP) expression is modulated by alternative mRNAs. RNA (New York, N.Y.) 15:1164–1176 - PMC - PubMed
    1. Boman K et al (2013) Decreased expression of RNA-binding motif protein 3 correlates with tumour progression and poor prognosis in urothelial bladder cancer. BMC Urol 13:17 - PMC - PubMed
    1. Derry JMJ et al (1995) RBM3 a novel human gene in Xp11.23 with a putative RNA-binding domain. Hum Mol Genet 4:2307–2311 - PubMed
    1. Ehlén A et al (2010) Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer. J Trans Med 8:78 - PMC - PubMed
    1. Ehlén Õ et al (2011) RBM3-regulated genes promote DNA integrity and affect clinical outcome in epithelial ovarian cancer. Transl Oncol 4:212 - PMC - PubMed

LinkOut - more resources